Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H20N4O.C7H8O3S.H2O |
Molecular Weight | 510.605 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CC1=CC=C(C=C1)S(O)(=O)=O.NC(=O)C2=CC=CC3=CN(N=C23)C4=CC=C(C=C4)[C@@H]5CCCNC5
InChI
InChIKey=ACNPUCQQZDAPJH-FMOMHUKBSA-N
InChI=1S/C19H20N4O.C7H8O3S.H2O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14;1-6-2-4-7(5-3-6)11(8,9)10;/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24);2-5H,1H3,(H,8,9,10);1H2/t14-;;/m1../s1
Molecular Formula | C7H8O3S |
Molecular Weight | 172.202 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C19H20N4O |
Molecular Weight | 320.3883 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 09:12:11 UTC 2023
by
admin
on
Sat Dec 16 09:12:11 UTC 2023
|
Record UNII |
195Q483UZD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C62554
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
EU/3/10/760(POSITIVE)
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | On 4 August 2010, orphan designation (EU/3/10/760) was granted by the European Commission to Merck Sharp & Dohme Limited, United Kingdom, for (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt (also known as MK-4827) for the treatment of ovarian cancer. The sponsorship was transferred to Tesaro U.K. Limited, United Kingdom, in December 2012. | ||
|
195Q483UZD
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
1613220-15-7
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
SUB183938
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
100000170106
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
74763937
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
m11995
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
DBSALT002590
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
C133238
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
176844
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | |||
|
EU/3/10/787(POSITIVE)
Created by
admin on Sat Dec 16 09:12:11 UTC 2023 , Edited by admin on Sat Dec 16 09:12:11 UTC 2023
|
PRIMARY | On 1 October 2010, orphan designation (EU/3/10/787) was granted by the European Commission to Merck Sharp & Dohme Limited, United Kingdom, for (3S)-3-{4-[7-(aminocarbonyl)-2H-indazol-2-yl] phenyl} piperidine tosylate monohydrate salt for the treatment of mantle-cell lymphoma. The sponsorship was transferred to Tesaro U.K. Limited, United Kingdom, in December 2012. |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|